FINWIRES · TerminalLIVE
FINWIRES

伊朗和平谈判陷入僵局,美国股市指数下跌

By

-- 周一午盘交易中,由于结束伊朗战争的谈判陷入僵局,原油期货价格上涨,打击了投资者信心,美国股市指数下跌。 纳斯达克综合指数下跌0.1%,至24,804.7点;标普500指数小幅下跌至7,162.5点;道琼斯工业平均指数下跌0.2%,至49,158.7点。 据Axios新闻报道,由于本周末在巴基斯坦举行的任何面对面会谈均告失败,伊朗提出了一项重开霍尔木兹海峡并结束战争的提议。Axios的报道援引了一位美国官员和两位知情人士的话。然而,该提议包括推迟两国之间的核谈判。 据CNN报道,两位消息人士透露,美国总统唐纳德·特朗普计划于今日会见国家安全高级官员,讨论伊朗提出的重开霍尔木兹海峡的新提议。 伊朗外长阿巴斯·阿拉格奇在访问巴基斯坦和阿曼后,前往俄罗斯与总统弗拉基米尔·普京会晤。据美国有线电视新闻网(CNN)报道,阿拉格奇向巴基斯坦官员列出了一系列“红线”,要求他们转达给美国,其中包括“核问题和霍尔木兹海峡问题”。 西德克萨斯中质原油期货价格上涨2.4%,至每桶96.64美元;布伦特原油期货价格上涨3.2%,至每桶108.73美元。

Related Articles

Insider Trading

Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing

Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml

$LFST
Australia

Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set

Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.

$CLS
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.

$AMP